ARGENX SE (1AE.DE) Stock Fundamental Analysis
Europe - FRA:1AE - NL0010832176 - Common Stock
729.2 EUR
+18 (+2.53%)
Taking everything into account, 1AE scores 6 out of 10 in our fundamental rating. 1AE was compared to 76 industry peers in the Biotechnology industry. While 1AE has a great health rating, its profitability is only average at the moment. 1AE has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year 1AE was profitable.
1AE had a positive operating cash flow in the past year.
In the past 5 years 1AE reported 4 times negative net income.
In the past 5 years 1AE always reported negative operating cash flow.
1.2 Ratios
1AE has a Return On Assets of 17.84%. This is amongst the best in the industry. 1AE outperforms 90.79% of its industry peers.
Looking at the Return On Equity, with a value of 21.00%, 1AE belongs to the top of the industry, outperforming 89.47% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 5.36%, 1AE is in the better half of the industry, outperforming 77.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROIC | 5.36% |
ROA(3y)-5.23%
ROA(5y)N/A
ROE(3y)-5.76%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 41.97%, 1AE belongs to the top of the industry, outperforming 93.42% of the companies in the same industry.
1AE has a better Operating Margin (15.30%) than 80.26% of its industry peers.
With an excellent Gross Margin value of 89.40%, 1AE belongs to the best of the industry, outperforming 85.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so 1AE is destroying value.
Compared to 1 year ago, 1AE has more shares outstanding
The debt/assets ratio for 1AE is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 30.50 indicates that 1AE is not in any danger for bankruptcy at the moment.
1AE has a Altman-Z score of 30.50. This is amongst the best in the industry. 1AE outperforms 96.05% of its industry peers.
1AE has a debt to FCF ratio of 0.14. This is a very positive value and a sign of high solvency as it would only need 0.14 years to pay back of all of its debts.
1AE has a Debt to FCF ratio of 0.14. This is amongst the best in the industry. 1AE outperforms 94.74% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that 1AE is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.01, 1AE belongs to the top of the industry, outperforming 81.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Altman-Z | 30.5 |
ROIC/WACC0.71
WACC7.52%
2.3 Liquidity
A Current Ratio of 5.60 indicates that 1AE has no problem at all paying its short term obligations.
The Current ratio of 1AE (5.60) is better than 81.58% of its industry peers.
A Quick Ratio of 5.27 indicates that 1AE has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.27, 1AE belongs to the top of the industry, outperforming 82.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 |
3. Growth
3.1 Past
1AE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 345.45%, which is quite impressive.
Looking at the last year, 1AE shows a very strong growth in Revenue. The Revenue has grown by 78.60%.
EPS 1Y (TTM)345.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%731.11%
Revenue 1Y (TTM)78.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%102.34%
3.2 Future
1AE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 103.72% yearly.
The Revenue is expected to grow by 32.89% on average over the next years. This is a very strong growth
EPS Next Y805.38%
EPS Next 2Y278.4%
EPS Next 3Y166.67%
EPS Next 5Y103.72%
Revenue Next Year85.31%
Revenue Next 2Y56.35%
Revenue Next 3Y43.79%
Revenue Next 5Y32.89%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 98.41, 1AE can be considered very expensive at the moment.
Based on the Price/Earnings ratio, 1AE is valued a bit cheaper than the industry average as 72.37% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of 1AE to the average of the S&P500 Index (27.69), we can say 1AE is valued expensively.
A Price/Forward Earnings ratio of 34.31 indicates a quite expensive valuation of 1AE.
1AE's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. 1AE is cheaper than 77.63% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.18, 1AE is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 98.41 | ||
| Fwd PE | 34.31 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1AE is valued a bit cheaper than the industry average as 71.05% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1AE indicates a somewhat cheap valuation: 1AE is cheaper than 76.32% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 169.5 | ||
| EV/EBITDA | 95.33 |
4.3 Compensation for Growth
1AE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as 1AE's earnings are expected to grow with 166.67% in the coming years.
PEG (NY)0.12
PEG (5Y)N/A
EPS Next 2Y278.4%
EPS Next 3Y166.67%
5. Dividend
5.1 Amount
No dividends for 1AE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:1AE (10/20/2025, 7:00:00 PM)
729.2
+18 (+2.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners41.51%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap44.90B
Analysts84.8
Price Target736.04 (0.94%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)7.11%
Max EPS beat(2)23.2%
EPS beat(4)3
Avg EPS beat(4)3962.36%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)1996.71%
EPS beat(12)8
Avg EPS beat(12)1343.38%
EPS beat(16)12
Avg EPS beat(16)1012.62%
Revenue beat(2)1
Avg Revenue beat(2)3.68%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)8.17%
Revenue beat(4)3
Avg Revenue beat(4)3.52%
Min Revenue beat(4)-0.81%
Max Revenue beat(4)8.17%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)-1.35%
EPS NQ rev (3m)N/A
EPS NY rev (1m)6.02%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0.19%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.96%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 98.41 | ||
| Fwd PE | 34.31 | ||
| P/S | 17.15 | ||
| P/FCF | 169.5 | ||
| P/OCF | 129.6 | ||
| P/B | 8.58 | ||
| P/tB | 8.9 | ||
| EV/EBITDA | 95.33 |
EPS(TTM)7.41
EY1.02%
EPS(NY)21.25
Fwd EY2.91%
FCF(TTM)4.3
FCFY0.59%
OCF(TTM)5.63
OCFY0.77%
SpS42.52
BVpS84.95
TBVpS81.9
PEG (NY)0.12
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROCE | 7.61% | ||
| ROIC | 5.36% | ||
| ROICexc | 14.9% | ||
| ROICexgc | 16.54% | ||
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% | ||
| FCFM | 10.12% |
ROA(3y)-5.23%
ROA(5y)N/A
ROE(3y)-5.76%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Debt/EBITDA | 0.07 | ||
| Cap/Depr | 428.74% | ||
| Cap/Sales | 3.12% | ||
| Interest Coverage | 519.07 | ||
| Cash Conversion | 82.6% | ||
| Profit Quality | 24.11% | ||
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 | ||
| Altman-Z | 30.5 |
F-Score5
WACC7.52%
ROIC/WACC0.71
Cap/Depr(3y)176.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)345.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%731.11%
EPS Next Y805.38%
EPS Next 2Y278.4%
EPS Next 3Y166.67%
EPS Next 5Y103.72%
Revenue 1Y (TTM)78.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%102.34%
Revenue Next Year85.31%
Revenue Next 2Y56.35%
Revenue Next 3Y43.79%
Revenue Next 5Y32.89%
EBIT growth 1Y96.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1305.72%
EBIT Next 3Y205.97%
EBIT Next 5Y117.35%
FCF growth 1Y67.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.31%
OCF growth 3YN/A
OCF growth 5YN/A